BET Protein Inhibitor RVX-208 Meets Primary Endpoint In SUSTAIN Clinical Trial
esverlogix Corp. today announced that the BET protein inhibitor RVX-208 significantly increased HDL-C (p=0.001), the primary endpoint of the SUSTAIN trial, a phase 2b clinical study. SUSTAIN also…